Biological networks and drug discovery - Where do we stand?

Drug Development Research

Volumn 75, Issue 5, 2014, Pages 271-282

  Geppert, Tim ^a   Koeppen, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

disease modifying therapies; drug discovery; network biology; systems biology

Indexed keywords

NEW DRUG;

DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; GENE INTERACTION; HUMAN; NETWORK BIOLOGY; NONHUMAN; ORGANIZATIONAL STRUCTURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; QUALITY OF LIFE; REVIEW; SYSTEMS BIOLOGY; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; SYSTEMS BIOLOGY;

EID: 84906688567     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21207     Document Type: Review

References (117)

1. Agoston V, Csermely P, Pongor S,. 2005. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys 71: 051909.
2. Albert R,. 2005. Scale-free networks in cell biology. J Cell Sci 118: 4947-4957.
3. Albert R, Jeong H, Barabasi AL,. 2001. Error and attack tolerance of complex networks. Nature 406: 378-382.
4. Araujo RP, Liotta LA, Petricoin EF,. 2007. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 6: 871-880.
5. Arrowsmith J,. 2011a. Trial watch phase II failures: 2008-2010. Nat Rev Drug Discov 10: 328-329.
6. Arrowsmith J,. 2011b. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 10: 87.
7. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH,. 2010. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther 9: 3137-3144.
8. Barabasi AL, Oltvai ZN,. 2004. Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113.
9. Barabasi AL, Gulbahce N, Loscalzo J,. 2011. Network medicine: a network-based approach to human disease. Nat Rev Genet 12: 56-68.
10. Berger B, Peng J, Singh M,. 2013. Computational solutions for omics data. Nat Rev Genet 14: 333-346.
11. Berntenis N, Ebeling M,. 2013. Detection of attractors of large Boolean networks via exhaustive enumeration of appropriate subspaces of the state space. BMC Bioinformatics 14: 361.
12. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, et al. 2012. Automated design of ligands to polypharmacological profiles. Nature 492: 215-220.
13. Campbell C, Albert R,. 2014. Stabilization of perturbed Boolean network attractors through compensatory interactions. BMC Syst Biol 8: 53.
14. Carter H, Hofree M, Ideker T,. 2013. Genotype to phenotype via network analysis. Curr Opin Genet Dev 23: 611-621.
15. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C,. 2008. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51: 347-372.
16. Choi M, Shi J, Jung SH, Chen X, Cho KH,. 2012. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage. Sci Signal 5: ra83.
17. Collins FS, Green ED, Guttmacher AE, Guyer MS,. 2003. A vision for the future of genomics research. Nature 422: 835-847.
18. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN,. 2014. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13: 419-431.
19. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JLY, Toufighi K, Mostafavi S, et al. 2010. The genetic landscape of a cell. Science 327: 425-431.
20. Csermely P, Agoston V, Pongor S,. 2005. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
21. Csermely P, Korcsmaros T, Kiss HJM, London G, Nussinov R,. 2013. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. Pharmacol Ther 138: 333-408.
22. Das J, Vo TV, Wei X, Mellor JC, Tong V, Degatano AG, Wang X, Wang L, Cordero NA, Kruer-Zerhusen N, et al. 2013. Cross-species protein interactome mapping reveals species-specific wiring of stress response pathways. Sci Signal 6: ra38.
23. Drake TA,. 2010. Genes and pathways contributing to obesity: a systems biology view. Prog Mol Biol Transl Sci 94: 9-38.
24. Ebert AD, Liang P, Wu JC,. 2012. Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol 60: 408-416.
25. Economist. 2014a. The backlash against big data. Economist. http://www.economist.com/blogs/economist-explains/2014/04/economist-explains-10 Accessed 20 April 2014.
26. Economist. 2014b. Costly cures. Economist, p. 71. http://www.economist. com/news/business/21603453-american-fight-over-expensive-new-treatments-has- global-implications-costly-cures Accessed 7 June 2014.
27. Eggert US,. 2013. The why and how of phenotypic small-molecule screens. Nat Chem Biol 9: 206-209.
28. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA,. 2009. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 8: 567-578.
29. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK,. 2006. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466.
30. Forda SR, Bergstroem R, Chlebus M, Barker R, Andersen PH,. 2013. Priorities for improving drug research, development and regulation. Nat Rev Drug Discov 12: 247-248.
31. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, et al. 2013. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41: D808-D815.
32. Garnier JP,. 2008. Rebuilding the R&D engine in big pharma. Harv Bus Rev 86: 68-70.
33. Gattrell W, Johnstone C, Patel S, Smith CS, Scheel A, Schindler M,. 2013. Designed multiple ligands in metabolic disease research: from concept to platform. Drug Discov Today 18: 692-696.
34. Gerlee P, Schmidt L, Monsefi N, Kling T, Joernsten R, Nelander S,. 2013. Searching for synergies: matrix algebraic approaches for efficient pair screening. PLoS ONE 8: e68598.
35. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL,. 2007. The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
36. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK,. 2012. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 109: 11178-11183, S11178-1.
37. Gujral TS, Peshkin L, Kirschner MW,. 2014. Exploiting polypharmacology for drug target deconvolution. Proc Natl Acad Sci U S A 111: 5048-5053.
38. Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H,. 2009. Structure of protein interaction networks and their implications on drug design. PLoS Comput Biol 5: e1000550.
39. He X, Zhang J,. 2006. Why do hubs tend to be essential in protein networks? PLoS Genet 2: 826-834.
40. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, et al. 2013. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3: 52-67.
41. Hopkins AL,. 2008. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
42. Hu Y, Bajorath J,. 2013. Compound promiscuity: what can we learn from current data? Drug Discov Today 18: 644-650.
43. Huttenhower C, Haley EM, Hibbs MA, Dumeaux V, Barrett DR, Coller HA, Troyanskaya OG,. 2009. Exploring the human genome with functional maps. Genome Res 19: 1093-1106.
44. Ideker T, Galitski T, Hood L,. 2001. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2: 343-372.
45. International Human Genome Sequencing Consortium. 2003. Finishing the euchromatic sequence of the human genome. Nature 431: 931-945.
46. Jenkins JK,. 2013. CDER new drug review: 2013 update. http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ UCM378227.pdf Accessed 22 July 2014.
47. Jenkins JL, Bender A, Davies JW,. 2006. In silico target fishing: predicting biological targets from chemical structure. Drug Discov Today Technol 3: 413-421.
48. Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ,. 2009. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
49. Jogalekar A,. 2014. Drug costs and prices: here we go again. Sci Am 2014, April 24. http://blogs.scientificamerican.com/the-curious-wavefunction/2014/04/ 24/drug-costs-and-prices-here-we-go-again/ Accessed 21 July 2014.
50. Keiser MJ, Irwin JJ, Shoichet BK,. 2010. The chemical basis of pharmacology. Biochemistry 49: 10267-10276.
51. Keith CT, Borisy AA, Stockwell BR,. 2005. Innovation: multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71-78.
52. Khanin R, Wit E,. 2006. How scale-free are biological networks. J Comput Biol 13: 810-818.
53. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD,. 2008. Genome-wide association studies: progress and potential for drug discovery and development. Nat Rev Drug Discov 7: 221-230.
54. Kitano H,. 2004. Biological robustness. Nat Rev Genet 5: 826-837.
55. Kitano H,. 2007. Towards a theory of biological robustness. Mol Syst Biol 3: 137.
56. Koehler S, Bauer S, Horn D, Robinson PN,. 2008. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82: 949-958.
57. Kokel D, Bryan J, Laggner C, White R, Cheung CY, Mateus R, Healey D, Kim S, Werdich AA, Haggarty SJ, et al. 2010. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol 6: 231-237.
58. Kola I, Landis J,. 2004. Opinion: can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-716.
59. Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young MP, Jenkins JL, Glick M, Glen RC, et al. 2011. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics 74: 2554-2574.
60. Lander ES,. 2011. Initial impact of the sequencing of the human genome. Nature 470: 187-197.
61. Lee I, Li Z, Marcotte EM,. 2007. An improved, bias-reduced probabilistic functional gene network of baker's yeast, Saccharomyces cerevisiae. PLoS ONE 2: e988.
62. Lee J, Bogyo M,. 2013. Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol 17: 118-126.
63. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ,. 2012a. Modern phenotypic drug discovery is a viable, neoclassical pharma strategy. J Med Chem 55: 4527-4538.
64. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB,. 2012b. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149: 780-794.
65. Lee MS,. 2012. Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs. In:, Barratt MJ, Frail DE, editors. Drug repositioning: bringing new life to shelved assets and existing drugs. Hoboken, NJ: Wiley, pp. 207-252.
66. Li Y, Agarwal P,. 2009. A pathway-based view of human diseases and disease relationships. PLoS ONE 4: e4346.
67. Linghu B, Snitkin ES, Hu Z, Xia Y, DeLisi C,. 2009. Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network. Genome Biol 10: R91.
68. Liu Z-P, Wang Y, Zhang X-S, Chen L,. 2012. Network-based analysis of complex diseases. IET Syst Biol 6: 22-33.
69. Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. 2014. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 111: 2349-2354.
70. McCoy JP Jr,. 2011. High-content screening: getting more from less. Nat Methods 8: 390-391.
71. McGonigle P, Ruggeri B,. 2014. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol 87: 162-171.
72. Medina-Franco JL, Giulianotti MA, Welmaker GS, Houghten RA,. 2013. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 18: 495-501.
73. Meng Q, Mäkinen V-P, Luk H, Yang X,. 2013. Systems biology approaches and applications in obesity, diabetes, and cardiovascular diseases. Curr Cardiovasc Risk Rep 7: 73-83.
74. Molinelli EJ, Korkut A, Wang W, Miller ML, Gauthier NP, Jing X, Kaushik P, He Q, Mills G, Solit DB, et al. 2013. Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput Biol 9: e1003290.
75. Moors EHM, Cohen AF, Schellekens H,. 2014. Towards a sustainable system of drug development. Drug Discov Today. doi: 10.1016/j.drudis.2014.03.004.
76. Morphy R,. 2010. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53: 1413-1437.
77. Morphy R, Rankovic Z,. 2005. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48: 6523-6543.
78. Morphy R, Kay C, Rankovic Z,. 2004. From magic bullets to designed multiple ligands. Drug Discov Today 9: 641-651.
79. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA,. 2011. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput Biol 7: e1001099.
80. Perez-Bercoff A, Hudson CM, Conant GC,. 2013. A conserved mammalian protein interaction network. PLoS ONE 8: e52581.
81. Peters JU,. 2013. Polypharmacology-foe or friend? J Med Chem 56: 8955-8971.
82. Prior M, Chiruta C, Currais A, Goldberg J, Ramsey J, Dargusch R, Maher PA, Schubert D., 2014. Back to the future with phenotypic screening. ACS Chem Neurosci 5: 503-513. doi: 10.1021/cn500051h.
83. Quinton-Tulloch MJ, Bruggeman FJ, Snoep JL, Westerhoff HV,. 2013. Trade-off of dynamic fragility but not of robustness in metabolic pathways in silico. FEBS J 280: 160-173.
84. Raue A, Schilling M, Bachmann J, Matteson A, Schelke M, Kaschek D, Hug S, Kreutz C, Harms BD, Theis FJ, et al. 2013. Lessons learned from quantitative dynamical modeling in systems biology. PLoS ONE 8: e74335.
85. Reddy AS, Zhang S,. 2013. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol 6: 41-47.
86. Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, Jang S, Haggarty SJ, Kokel D, Rubin LL, Peterson RT, et al. 2010. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327: 348-351.
87. Ringel M, Tollman P, Hersch G, Schulze U,. 2013. Does size matter in R&D productivity? If not, what does? Nat Rev Drug Discov 12: 901-902.
88. Roth BL, Sheffler DJ, Kroeze WK,. 2004. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359.
89. Sams-Dodd F,. 2013. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today 18: 211-217.
90. Santiago JA, Potashkin JA,. 2013. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS ONE 8: e83940.
91. Scannell JW, Blanckley A, Boldon H, Warrington B,. 2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11: 191-200.
92. Schneider HC, Klabunde T,. 2013. Understanding drugs and diseases by systems biology? Bioorg Med Chem Lett 23: 1168-1176.
93. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, et al. 2009. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2: ra31.
94. Schulze U, Baedeker M, Chen YT, Greber D,. 2014. R&D productivity: on the comeback trail. Nat Rev Drug Discov 13: 331-332.
95. Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, et al. 2014. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. J Clin Oncol 32: 5s.
96. Swinney DC, Anthony J,. 2011. How were new medicines discovered? Nat Rev Drug Discov 10: 507-519.
97. Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, Aittokallio T,. 2013. Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol 9: e1003226.
98. Terstappen GC, Schluepen C, Raggiaschi R, Gaviraghi G,. 2007. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6: 891-903.
99. Turan N, Kalko S, Stincone A, Clarke K, Sabah A, Howlett K, Curnow SJ, Rodriguez DA, Cascante M, O'Neill L, et al. 2011. A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease. PLoS Comput Biol 7: e1002129.
100. van Reil NAW,. 2006. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief Bioinform 7: 364-374.
101. Visscher PM, Brown MA, McCarthy MI, Yang J,. 2012. Five years of GWAS discovery. Am J Hum Genet 90: 7-24.
102. Wang K, Narayanan M, Zhong H, Tompa M, Schadt EE, Zhu J,. 2009. Meta-analysis of inter-species liver co-expression networks elucidates traits associated with common human diseases. PLoS Comput Biol 5: e1000616.
103. Williams M,. 2011. Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther 336: 3-8.
104. Winquist RJ, Mullan M, Williams M,. 2014. The fall and rise of pharmacology-(re-)defining the discipline? Biochem Pharmacol 87: 4-24.
105. Woodcock J, Griffin JP, Behrman RE,. 2011. Perspective: development of novel combination therapies. N Engl J Med 364: 985-987.
106. Xie L, Li J, Xie L, Bourne PE,. 2009. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 5: e1000387.
107. Xie L, Xie L, Bourne PE,. 2011. Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol 21: 189-199.
108. Xie L, Xie L, Kinnings SL, Bourne PE,. 2012. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52: 361-379.
109. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M,. 2007. Drug-target network. Nat Biotechnol 25: 1119-1126.
110. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, et al. 2008. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 4: 59-68.
111. Young RM, Staudt LM,. 2013. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12: 229-243.
112. Yuan R, Lin Y,. 2000. Traditional Chinese medicine an approach to scientific proof and clinical validation. Pharmacol Ther 86: 191-198.
113. Zanella F, Lorens JB, Link W,. 2010. High content screening: seeing is believing. Trends Biotechnol 5: 237-245.
114. Zhang B, Horvath S,. 2005. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4: 17.
115. Zheng W, Thorne N, McKew JC,. 2013. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 18: 1067-1073.
116. Zimmermann GR, Lehar J, Keith CT,. 2006. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42.
117. Zotenko E, Mestre J, O'Leary DP, Przytycka TM,. 2008. Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality. PLoS Comput Biol 4: e1000140.